Drugs that contain Tazemetostat Hydrobromide

1. List of Tazverik drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9090562 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US11052093 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10821113 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US9394283 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US8410088 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Aug, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333217 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US8691507 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof
Sep, 2031

(8 years from now)

US9175331 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US9949999 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US8895245 EPIZYME INC Inhibitors of human EZH2 and methods of use thereof
Sep, 2031

(8 years from now)

US9334527 EPIZYME INC Inhibitors of human EZH2, and methods of use thereof
Sep, 2031

(8 years from now)

US9855275 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10420775 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US8765732 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9522152 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10155002 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9549931 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10245269 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US9872862 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US11491163 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US9688665 EPIZYME INC Methods of treating cancer
Aug, 2034

(11 years from now)

US9889138 EPIZYME INC Method for treating cancer
Oct, 2035

(12 years from now)

US10369155 EPIZYME INC Method for treating cancer
Oct, 2035

(12 years from now)

US10786511 EPIZYME INC Method for treating cancer
Dec, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 23, 2025
New Indication (I) Jun 18, 2023
Orphan Drug Exclusivity (ODE) Jan 23, 2027

NCE-1 date: January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma; Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma by inhibiting enhancer of zeste homolog 2 (ezh2); Method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2; Method of treating lymphoma; Method of treating sarcoma; Method of treating follicular lymphoma

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic